Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Alice Tisserand, Frédéric Blanc, Mary Mondino, Candice Muller, Hélène Durand, Catherine Demuynck, Paulo Loureiro de Sousa, Alix Ravier, Léa Sanna, Anne Botzung, Nathalie Philippi
BACKGROUND: Dementia with Lewy bodies (DLB) is characterized by insular atrophy, which occurs at the early stage of the disease. Damage to the insula has been associated with disorders reflecting impairments of the most fundamental components of the self, such as anosognosia, which is a frequently reported symptom in patients with Lewy bodies (LB). The purpose of this study was to investigate modifications of the self-concept (SC), another component of the self, and to identify neuroanatomical correlates, in prodromal to mild DLB...
April 19, 2024: Alzheimer's Research & Therapy
#2
JOURNAL ARTICLE
Zhen Liu, Dai Shi, Yue Cai, Anqi Li, Guoyu Lan, Pan Sun, Lin Liu, Yalin Zhu, Jie Yang, Yajing Zhou, Lizhi Guo, Laihong Zhang, Shuqing Deng, Shuda Chen, Xianfeng Yu, Xuhui Chen, Ruiyue Zhao, Qingyong Wang, Pengcheng Ran, Linsen Xu, Liemin Zhou, Kun Sun, Xinlu Wang, Qiyu Peng, Ying Han, Tengfei Guo
INTRODUCTION: The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer's disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort. METHODS: Following the standard protocols of the Alzheimer's Disease Neuroimaging Initiative, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) was initiated in 2021...
April 16, 2024: Alzheimer's Research & Therapy
#3
JOURNAL ARTICLE
Xiaoling Wang, Xiaomin Zhang, Jing Liu, Jingjing Zhang, Congcong Liu, Yuting Cui, Qiao Song, Yuli Hou, Yaqi Wang, Qian Zhang, Yingzhen Zhang, Yujian Fan, Jianping Jia, Peichang Wang
BACKGROUND: Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early diagnostic biomarkers. In this study, synaptic vesicle glycoprotein 2 A (SV2A) was examined to improve the early diagnostic efficiency in AD. METHODS: In this study, biomarker testing was performed through the single-molecule array (Simoa). A total of 121 subjects including cognitively unimpaired controls, amnestic mild cognitive impairment (aMCI), AD and other types of dementia underwent cerebrospinal fluid (CSF) SV2A testing; 430 subjects including health controls, aMCI, AD and other types of dementia underwent serum SV2A, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and p-tau217 testing; 92 subjects including aMCI and AD underwent both CSF SV2A and serum SV2A testing; 115 cognitively unimpaired subjects including APOE ε4 carriers and APOE ε4 non-carriers were tested for serum SV2A, GFAP, NfL and p-tau217...
April 13, 2024: Alzheimer's Research & Therapy
#4
JOURNAL ARTICLE
Joel Eyamu, Wuon-Shik Kim, Kahye Kim, Kun Ho Lee, Jaeuk U Kim
BACKGROUND: The worldwide trend of demographic aging highlights the progress made in healthcare, albeit with health challenges like Alzheimer's Disease (AD), prevalent in individuals aged 65 and above. Its early detection at the mild cognitive impairment (MCI) stage is crucial. Event-related potentials (ERPs) obtained by averaging EEG segments responded to repeated events are vital for cognitive impairment research. Consequently, examining intra-trial ERP variability is vital for comprehending fluctuations within psychophysiological processes of interest...
April 13, 2024: Alzheimer's Research & Therapy
#5
REVIEW
Zsolt Huszár, Marie Anne Engh, Márk Pavlekovics, Tomoya Sato, Yalea Steenkamp, Bernard Hanseeuw, Tamás Terebessy, Zsolt Molnár, Péter Hegyi, Gábor Csukly
BACKGROUND: Measurement of beta-amyloid (Aβ) and phosphorylated tau (p-tau) levels offers the potential for early detection of neurocognitive impairment. Still, the probability of developing a clinical syndrome in the presence of these protein changes (A+ and T+) remains unclear. By performing a systematic review and meta-analysis, we investigated the risk of mild cognitive impairment (MCI) or dementia in the non-demented population with A+ and A- alone and in combination with T+ and T- as confirmed by PET or cerebrospinal fluid examination...
April 12, 2024: Alzheimer's Research & Therapy
#6
JOURNAL ARTICLE
Christian Sandøe Musaeus, Troels Wesenberg Kjaer, Ulrich Lindberg, Mark B Vestergaard, Henrik Bo, Wiberg Larsson, Daniel Zvi Press, Birgitte Bo Andersen, Peter Høgh, Preben Kidmose, Martin Christian Hemmsen, Mike Lind Rank, Steen Gregers Hasselbalch, Gunhild Waldemar, Kristian Steen Frederiksen
BACKGROUND: In epilepsy, the ictal phase leads to cerebral hyperperfusion while hypoperfusion is present in the interictal phases. Patients with Alzheimer's disease (AD) have an increased prevalence of epileptiform discharges and a study using intracranial electrodes have shown that these are very frequent in the hippocampus. However, it is not known whether there is an association between hippocampal hyperexcitability and regional cerebral blood flow (rCBF). The objective of the study was to investigate the association between rCBF in hippocampus and epileptiform discharges as measured with ear-EEG in patients with Alzheimer's disease...
April 12, 2024: Alzheimer's Research & Therapy
#7
JOURNAL ARTICLE
Sebastian Moguilner, Rubén Herzog, Yonatan Sanz Perl, Vicente Medel, Josefina Cruzat, Carlos Coronel, Morten Kringelbach, Gustavo Deco, Agustín Ibáñez, Enzo Tagliazucchi
BACKGROUND: The hypothesis of decreased neural inhibition in dementia has been sparsely studied in functional magnetic resonance imaging (fMRI) data across patients with different dementia subtypes, and the role of social and demographic heterogeneities on this hypothesis remains to be addressed. METHODS: We inferred regional inhibition by fitting a biophysical whole-brain model (dynamic mean field model with realistic inter-areal connectivity) to fMRI data from 414 participants, including patients with Alzheimer's disease, behavioral variant frontotemporal dementia, and controls...
April 11, 2024: Alzheimer's Research & Therapy
#8
JOURNAL ARTICLE
Motonobu Fujishima, Yohei Kawasaki, Toshiharu Mitsuhashi, Hiroshi Matsuda
BACKGROUND: Individuals on the preclinical Alzheimer's continuum, particularly those with both amyloid and tau positivity (A + T +), display a rapid cognitive decline and elevated disease progression risk. However, limited studies exist on brain atrophy trajectories within this continuum over extended periods. METHODS: This study involved 367 ADNI participants grouped based on combinations of amyloid and tau statuses determined through cerebrospinal fluid tests...
April 10, 2024: Alzheimer's Research & Therapy
#9
JOURNAL ARTICLE
Chang Liu, Alfredo Cárdenas-Rivera, Shayna Teitelbaum, Austin Birmingham, Mohammed Alfadhel, Mohammad A Yaseen
BACKGROUND: Neuroinflammation, impaired metabolism, and hypoperfusion are fundamental pathological hallmarks of early Alzheimer's disease (AD). Numerous studies have asserted a close association between neuroinflammation and disrupted cerebral energetics. During AD progression and other neurodegenerative disorders, a persistent state of chronic neuroinflammation reportedly exacerbates cytotoxicity and potentiates neuronal death. Here, we assessed the impact of a neuroinflammatory challenge on metabolic demand and microvascular hemodynamics in the somatosensory cortex of an AD mouse model...
April 10, 2024: Alzheimer's Research & Therapy
#10
REVIEW
Menka Sebalj, Ali Lakhani, Andrea Grindrod, Rwth Stuckey
BACKGROUND: Dementia has a significant impact on the social, physical, and psychological wellbeing of people living with dementia, their families and society. Animal-assisted interventions can have positive effects on the health and wellbeing of people living with dementia. Equine-assisted services are animal-assisted non-pharmacological interventions which have improved the health and wellbeing of diverse populations. The impact of participating in equine-assisted services on the health and wellbeing of people with dementia is unclear...
April 9, 2024: Alzheimer's Research & Therapy
#11
MULTICENTER STUDY
Aniek M van Gils, Hanneke F M Rhodius-Meester, Dédé Handgraaf, Heleen M A Hendriksen, Astrid van Strien, Niki Schoonenboom, Annemieke Schipper, Mariska Kleijer, Annemiek Griffioen, Majon Muller, Antti Tolonen, Jyrki Lötjönen, Wiesje M van der Flier, Leonie N C Visser
BACKGROUND: Both memory clinic professionals and patients see value in digital tools, yet these hardly find their way to clinical practice. We explored the usability of a digital tool to support the diagnostic work-up in daily memory clinic practice. We evaluated four modules that integrate multi-modal patient data (1.cognitive test; cCOG, and 2. MRI quantification; cMRI) into useful diagnostic information for clinicians (3. cDSI) and understandable and personalized information for patients (4...
April 8, 2024: Alzheimer's Research & Therapy
#12
JOURNAL ARTICLE
Neus Falgàs, Luca Sacchi, Tiziana Carandini, Nuria Montagut, Giorgio Conte, Fabio Triulzi, Daniela Galimberti, Andrea Arighi, Raquel Sanchez-Valle, Giorgio Giulio Fumagalli
INTRODUCTION: Differential diagnosis among subjects with Primary Progressive Aphasia (PPA) can be challenging. Structural MRI can support the clinical profile. Visual rating scales are a simple and reliable tool to assess brain atrophy in the clinical setting. The aims of the study were to establish to what extent the visual rating scales could be useful in the differential diagnosis of PPA, to compare the clinical diagnostic impressions derived from routine MRI interpretations with those obtained using the visual rating scale and to correlate results of the scales in a voxel-based morphometry (VBM) analysis...
April 6, 2024: Alzheimer's Research & Therapy
#13
JOURNAL ARTICLE
Kanishk Kaushik, Anna M de Kort, Rosemarie van Dort, Reinier G J van der Zwet, Bob Siegerink, Sabine Voigt, Erik W van Zwet, Maaike C van der Plas, Emma A Koemans, Ingeborg Rasing, Roy P C Kessels, Huub A M Middelkoop, Floris H B M Schreuder, Catharina J M Klijn, Marcel M Verbeek, Gisela M Terwindt, Ellis S van Etten, Marieke J H Wermer
BACKGROUND: Neuropsychiatric symptoms (NPS) may affect cognition, but their burden in cerebral amyloid angiopathy (CAA), one of the main causes of intracerebral hemorrhage (ICH) and dementia in the elderly, remains unclear. We investigated NPS, with emphasis on apathy and irritability in sporadic (sCAA) and Dutch-type hereditary (D-)CAA. METHODS: We included patients with sCAA and (pre)symptomatic D-CAA, and controls from four prospective cohort studies. We assessed NPS per group, stratified for history of ICH, using the informant-based Neuropsychiatric Inventory (NPI-Q), Starkstein Apathy scale (SAS), and Irritability Scale...
April 6, 2024: Alzheimer's Research & Therapy
#14
JOURNAL ARTICLE
Min Chu, Deming Jiang, Haitian Nan, Lulu Wen, Li Liu, Miao Qu, Liyong Wu
BACKGROUND: Vascular dysfunction was recently reported to be involved in the pathophysiological process of neurodegenerative diseases, but its role in sporadic behavioral variant frontotemporal dementia (bvFTD) remains unclear. The aim of this study was to systematically explore vascular dysfunction, including changes in white matter hyperintensities (WMHs) and peripheral vascular markers in bvFTD. METHODS: Thirty-two patients with bvFTD who with no vascular risk factors were enrolled in this cross-sectional study and assessed using positron emission tomography/magnetic resonance (PET/MRI) imaging, peripheral plasma vascular/inflammation markers, and neuropsychological examinations...
April 5, 2024: Alzheimer's Research & Therapy
#15
JOURNAL ARTICLE
Douglas M Lopes, Jack A Wells, Da Ma, Lauren Wallis, Daniel Park, Sophie K Llewellyn, Zeshan Ahmed, Mark F Lythgoe, Ian F Harrison
BACKGROUND: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach...
April 5, 2024: Alzheimer's Research & Therapy
#16
JOURNAL ARTICLE
Heather M Terron, Sagar J Parikh, Samer O Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Dennis W Dickson, Paul Saftig, Frank M LaFerla, Shelley Lane, Malcolm A Leissring
BACKGROUND: Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid-β protein (Aβ) and the microtubule-associated protein, tau, which accumulate pathognomonically in Alzheimer disease (AD), but few studies have examined the role of CatD in the development of Aβ pathology and tauopathy in vivo. METHODS: CatD knockout (KO) mice were crossed to human amyloid precursor protein (hAPP) transgenic mice, and amyloid burden was quantified by ELISA and immunohistochemistry (IHC)...
April 4, 2024: Alzheimer's Research & Therapy
#17
JOURNAL ARTICLE
Jose L Cantero, Mercedes Atienza, Isabel Sastre, María Jesús Bullido
BACKGROUND: Mounting data suggests that herpes simplex virus type 1 (HSV-1) is involved in the pathogenesis of AD, possibly instigating amyloid-beta (Aβ) accumulation decades before the onset of clinical symptoms. However, human in vivo evidence linking HSV-1 infection to AD pathology is lacking in normal aging, which may contribute to the elucidation of the role of HSV-1 infection as a potential AD risk factor. METHODS: To shed light into this question, serum anti-HSV IgG levels were correlated with 18 F-Florbetaben-PET binding to Aβ deposits and blood markers of neurodegeneration (pTau181 and neurofilament light chain) in cognitively normal older adults...
April 3, 2024: Alzheimer's Research & Therapy
#18
JOURNAL ARTICLE
Qingze Zeng, Yanbo Wang, Shuyue Wang, Xiao Luo, Kaicheng Li, Xiaopei Xu, Xiaocao Liu, Luwei Hong, Jixuan Li, Zheyu Li, Xinyi Zhang, Siyan Zhong, Zhirong Liu, Peiyu Huang, Yanxing Chen, Minming Zhang
BACKGROUND: Neuropsychiatric symptoms (NPS) are prevalent in cognitively impaired individuals including Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI). Whereas several studies have reported the associations between NPS with AD pathologic biomarkers and cerebral small vessel disease (SVD), but it remains unknown whether AD pathology and SVD contribute to different sub-syndromes independently or aggravate same symptoms synergistically. METHOD: We included 445 cognitively impaired individuals (including 316 MCI and 129 AD) with neuropsychiatric, cerebrospinal fluid (CSF) biomarkers (Aβ42, p-tau, and t-tau) and multi-model MRI data...
April 3, 2024: Alzheimer's Research & Therapy
#19
JOURNAL ARTICLE
Dario Bachmann, Bettina von Rickenbach, Andreas Buchmann, Martin Hüllner, Isabelle Zuber, Sandro Studer, Antje Saake, Katrin Rauen, Esmeralda Gruber, Roger M Nitsch, Christoph Hock, Valerie Treyer, Anton Gietl
BACKGROUND: White matter hyperintensities (WMHs) are often measured globally, but spatial patterns of WMHs could underlie different risk factors and neuropathological and clinical correlates. We investigated the spatial heterogeneity of WMHs and their association with comorbidities, Alzheimer's disease (AD) risk factors, and cognition. METHODS: In this cross-sectional study, we studied 171 cognitively unimpaired (CU; median age: 65 years, range: 50 to 89) and 51 mildly cognitively impaired (MCI; median age: 72, range: 53 to 89) individuals with available amyloid (18F-flutementamol) PET and FLAIR-weighted images...
April 1, 2024: Alzheimer's Research & Therapy
#20
JOURNAL ARTICLE
Imogen J Swift, Rosa Rademakers, NiCole Finch, Matt Baker, Roberta Ghidoni, Luisa Benussi, Giuliano Binetti, Giacomina Rossi, Matthis Synofzik, Carlo Wilke, David Mengel, Caroline Graff, Leonel T Takada, Raquel Sánchez-Valle, Anna Antonell, Daniela Galimberti, Chiara Fenoglio, Maria Serpente, Marina Arcaro, Stefanie Schreiber, Stefan Vielhaber, Philipp Arndt, Isabel Santana, Maria Rosario Almeida, Fermín Moreno, Myriam Barandiaran, Alazne Gabilondo, Johannes Stubert, Estrella Gómez-Tortosa, Pablo Agüero, M José Sainz, Tomohito Gohda, Maki Murakoshi, Nozomu Kamei, Sarah Kittel-Schneider, Andreas Reif, Johannes Weigl, Jinlong Jian, Chuanju Liu, Ginette Serrero, Thomas Greither, Gerit Theil, Ebba Lohmann, Stefano Gazzina, Silvia Bagnoli, Giovanni Coppola, Amalia Bruni, Mirja Quante, Wieland Kiess, Andreas Hiemisch, Anne Jurkutat, Matthew S Block, Aaron M Carlson, Geir Bråthen, Sigrid Botne Sando, Gøril Rolfseng Grøntvedt, Camilla Lauridsen, Amanda Heslegrave, Carolin Heller, Emily Abel, Alba Gómez-Núñez, Roger Puey, Andrea Arighi, Enmanuela Rotondo, Lize C Jiskoot, Lieke H H Meeter, João Durães, Marisa Lima, Miguel Tábuas-Pereira, João Lemos, Bradley Boeve, Ronald C Petersen, Dennis W Dickson, Neill R Graff-Radford, Isabelle LeBer, Leila Sellami, Foudil Lamari, Fabienne Clot, Barbara Borroni, Valentina Cantoni, Jasmine Rivolta, Alberto Lleó, Juan Fortea, Daniel Alcolea, Ignacio Illán-Gala, Lucie Andres-Cerezo, Philip Van Damme, Jordi Clarimon, Petra Steinacker, Emily Feneberg, Markus Otto, Emma L van der Ende, John C van Swieten, Harro Seelaar, Henrik Zetterberg, Aitana Sogorb-Esteve, Jonathan D Rohrer
BACKGROUND: Pathogenic heterozygous mutations in the progranulin gene (GRN) are a key cause of frontotemporal dementia (FTD), leading to significantly reduced biofluid concentrations of the progranulin protein (PGRN). This has led to a number of ongoing therapeutic trials aiming to treat this form of FTD by increasing PGRN levels in mutation carriers. However, we currently lack a complete understanding of factors that affect PGRN levels and potential variation in measurement methods. Here, we aimed to address this gap in knowledge by systematically reviewing published literature on biofluid PGRN concentrations...
March 28, 2024: Alzheimer's Research & Therapy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
